🔗 Permalink

Inventor profile of:

Mathieu Blery

City:

Marseille

Country:

France

Published Applications:

Last publication date:

2024-12-26

Top Assignees for applications by Mathieu Blery

The entities that hold a legal rights for patent applications filed by inventor Blery Mathieu:

INNATE PHARMA 11 Marseilles, France
Innate Pharma 3 Marseille, France
Innate Pharma, S.A. 2 Marseilles, France
UNIVERSITA DI GENOVA 1 Genova, Italy
Novo Nordisk A/S 1 Bagsvaerd, Denmark
University of Genova 1 Genoa, Italy
BRISTOL-MYERS SQUIBB COMPANY 1 Princeton, NJ United States
Innate Pharma SA 1 Marseille, France

Recent patent applications by Blery Mathieu

Mathieu Blery from Marseille, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2024-12-26

US20240425586A1

Chemistry; metallurgy

TREATMENT OF PERIPHERAL T CELL LYMPHOMA

#2 | 2024-11-07

US20240368281A1

Chemistry; metallurgy

TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES

#3 | 2023-09-28

US20230303691A1

Chemistry; metallurgy

NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES

#4 | 2023-07-27

US20230235060A1

Chemistry; metallurgy

NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES

#5 | 2022-10-27

US20220340661A1

Chemistry; metallurgy

NKp46 BINDING AGENTS

#6 | 2021-08-05

US20210238285A1

Chemistry; metallurgy

Treatment regimens using anti-NKG2A antibodies

#7 | 2021-04-29

US20210122821A1

Chemistry; metallurgy

NEUTRALIZATION OF INHIBITORY PATHWAYS IN LYMPHOCYTES

#8 | 2020-10-22

US20200332008A1

Chemistry; metallurgy

Neutralization of inhibitory pathways in lymphocytes

#9 | 2020-09-24

US20200299383A1

Chemistry; metallurgy

TREATMENT REGIMENS USING ANTI-NKG2A ANTIBODIES

#10 | 2020-09-24

US20200299380A1

Chemistry; metallurgy

MICA BINDING AGENTS

#11 | 2020-01-23

US20200023071A1

Human necessities

IMMUNOMODULATORY ANTIBODY DRUG CONJUGATES BINDING TO A HUMAN MICA POLYPEPTIDE

#12 | 2019-12-05

US20190367609A1

Chemistry; metallurgy

NKp46 binding agents

#13 | 2019-10-24

US20190322744A1

Chemistry; metallurgy

Treatment of cancers using anti-NKG2A agents

#14 | 2019-10-17

US20190315857A1

Chemistry; metallurgy

Treatment of peripheral T cell lymphoma

#15 | 2019-01-31

US20190031755A1

Chemistry; metallurgy

Neutralization of inhibitory pathways in lymphocytes

#16 | 2017-11-02

US20170313773A1

Chemistry; metallurgy

Treatment of cancers using anti-NKG2A agents

#17 | 2017-10-19

US20170298131A1

Chemistry; metallurgy

Treatment regimens using anti-NKG2A antibodies

#18 | 2017-10-12

US20170291947A1

Chemistry; metallurgy

Neutralization of inhibitory pathways in lymphocytes

#19 | 2017-09-21

US20170267764A1

Chemistry; metallurgy

ANTI-MICA ANTIBODIES

#20 | 2016-09-08

US20160257750A1

Chemistry; metallurgy

Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma

#21 | 2015-12-31

US20150376274A1

Chemistry; metallurgy

Treatment of peripheral T cell lymphoma

#22 | 2015-07-09

US20150191542A1

Chemistry; metallurgy

Mica binding agents

#23 | 2008-11-06

US20080274047A1

Chemistry; metallurgy

Compositions and methods for treating proliferative disorders

#24 | 2008-08-14

US20080196111A1

Chemistry; metallurgy

Expression Vectors and Methods for Obtaining Nk Cell Specific Expression

InventorID:

1219892 ⎘